Image Image Image Image Image Image Image Image Image Image
Access
Up

Up

Foto44_3

· 20/12/2014

MPL4 GA: A phase I study in subjects with geographic atrophy secondary to dry age-related macular degeneration  

Foto49_3

· 20/12/2014

Oral Omega 3 GA. A phase II in subjects with geographic atrophy secondary to AMD

Queratitis

· 02/07/2014

Clinical Trial M-13-027: Evaluation of Clinical Outcomes Following Treatment with Systane® Balance in Dry Eye Subjects with Lipid Deficiency

Glaucoma_Nervioptic1_PORTADA

· 02/07/2014

Prospective, randomised, placebo-controlled, double-masked, three-armed, multicenter Phase II/III trial to establish the safety and efficacy of a topical treatment of Neovascular Glaucoma

Traccio macular

· 02/07/2014

JETREA M-13-056 Assessment of anatomical and functional outcomes in patients treated with ocriplasmin for vitreomacular traction/symptomatic vitreomacular adhesion

Foto3

· 19/03/2014

TREND: A phase IIIb, randomized, a 12-month, Visual Acuity assessor-masked, interventional study assessing the efficacy and safety of the Treat and Extend vs monthly regimens of 0.5 mg ranibizumab in patients with newly diagnosed nAMD

Foto1_def2

· 19/03/2014

MACBETH. Phase IV Study to evaluate the efficacy of aflibercept in subjects with neovascular Age-related Macular Degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy

Foto51_2

· 26/03/2013

GAIN. Characterization of geographic atrophy progression in patients with age-related macular degeneration: evolution and risk factors associated with geographic atrophy progression

Foto49_3

· 26/03/2013

Oral Omega 3 Drusen: A phase II randomized, double-mask study to establish the safety and efficacy of High-Dose Oral Omega 3 in subjects with high-risk drusen secondary to dry age-related macular degeneration 

Foto46-2

· 26/03/2013

The Brighter Study: a 24-month, phase IIIB, open-label, randomized, active controlled, three-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven pro re nata dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO)

Foto46_3

· 26/03/2013

The Crystal Study: a 24-month, phase IIIB, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven pro re nata dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)

Foto45_2

· 26/03/2013

MPL4 DRUSEN. A phase I study to establish the safety and efficacy of retinal pigment epithelium micropulse laser in subjects with high-risk drusen secondary to age-related macular degeneration 

Foto43_1

· 26/03/2013

Translational research in regenerative stem cell therapies for retinal degenerative diseases: from the swine animal model of retinal atrophy to clinical trials in human patients with age-related macular degeneration, retinitis pigmentosa and Stargardt’s disease

Foto42_3

· 26/03/2013

GAP. A phase I escalating dose of subretinal sodium iodate: a toxi-induced animal model of geography atrophy of RPE and phtotoreceptors

_MG_7643

· 26/03/2013

Pilot phase II clinical trial to evalute safety of human fetal retinal transplant in the treatment of geographic atrophy secondary to age-related macular degeneration and retinitis pigmentosa

Last modified: 11 June, 2019 - 8:44